contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment CompanyTagList on Company {
  pageUrl
  name
  viewerIsFollowing
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    ...CompanyTagList
    id
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls {
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      defaultInstrument {
        isin
        id
      }
      id
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    id
    name
    viewerIsFollowing
    defaultInstrument {
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


demant-as-justerede-sammenligningstal-for-2023

__typename

title

isPremium

lang

htmlBody

companies

createdAt

publishers

authors

reactionGroups

pageUrl

alternatePageUrls

imgUrl

description

Demant er aktiv inden for medicinsk teknologi. Virksomheden har specialiseret sig i udvikling af høreapparater. I dag opererer virksomheden på globalt plan, hvor produkterne sælges under forskellige mærker som Bernafon og Sonice. Produkterne tilgås via virksomhedens distributører og salgskanaler. Ud over hovedaktiviteterne forsker virksomheden inden for diagnostik til måling af hørelseskvalitet. Virksomheden blev grundlagt i 1904 og har hovedkontor med beliggenhed i Smørum.

Demant

1.8.2024 11:49:37 CEST | Demant A/S | Investor NyhederInvestor news1. august 2024Justerede sammenligningstal for 2023 Den 5. februar 2024 meldte Demant ud, at man havde besluttet at gennemfø...

<p class="prs-announcement__byline">1.8.2024 11:49:37 CEST | Demant A/S |    Investor Nyheder</p><table class="prs-table"><tbody><tr><td><p><strong>Investor news</strong></p></td><td><p><strong>1. august 2024</strong></p></td></tr></tbody></table><p><strong>Justerede sammenligningstal for 2023</strong></p><p>&nbsp;</p><p>Den 5. februar 2024 meldte Demant ud, at man havde besluttet at gennemføre en evaluering af de strategiske muligheder for Communications-forretningsområdet. I henhold til <em>IFRS 5 – </em><em>Anlægsaktiver bestemt for salg og ophørte aktiviteter</em> og som tidligere meldt ud indregnes Communications derfor i koncernens finansielle rapportering og regnskab som en ophørende aktivitet sammen med Hearing Implants, og sammenligningstallene for 2023 er justeret for at afspejle dette. Med henblik på afstemning af disse tal med de rapporterede tal har vi vedhæftet justerede resultatopgørelser og opgørelse over frie pengestrømme før virksomhedsopkøb (ureviderede) for følgende rapporteringsperioder: H1 2023, H2 2023 og FY 2023.</p><p>&nbsp;</p><table class="prs-table"><tbody><tr><td><p><em>Yderligere information:</em></p><p>Søren Nielsen, koncernchef &amp; adm. direktør</p><p>Telefon +45 3917 7300</p><p><a href="http://www.demant.com">www.demant.com</a></p></td><td><p><em>Øvrige kontaktpersoner:</em></p><p>René Schneider, CFO</p><p>Peter Pudselykke, Head of Investor Relations</p><p>Henrik Axel Lynge Buchter, Manager of External Communications</p></td></tr></tbody></table><p><strong>&nbsp;</strong></p><h4>Kontakter</h4><ul>    <li>        Henrik Axel Lynge Buchter, External Communication Manager, Corporate Communication &amp; Sustainability, +45 2264 9982, <a href="mailto:heey@demant.com">heey@demant.com</a>    </li></ul><h4>Om Demant A/S</h4><p>Demant is a world-leading hearing healthcare group that offers solutions and services to help people with hearing loss connect with the world around them. In every aspect, from hearing devices, hearing implants, diagnostics to audio and video solutions and hearing care all over the world, Demant is active and engaged. Our innovative technologies and know-how help improve people’s health and hear-ing. We create life-changing differences through hearing health.</p><h4>Vedhæftninger</h4><ul>    <li>        <a href="https://via.ritzau.dk/ir-files/13560112/13972577/13730/240731%20Investor%20news%20-%20sammenligningstal%20for%202023.pdf">240731 Investor news - sammenligningstal for 2023.pdf</a>    </li></ul>

Demant A/S: Justerede sammenligningstal for 2023

Probabilities of success in drug development

Return on capital (ROE, ROI, ROIC, RONIC)

Drug development investment: Value creation through M&As and licensing agreements

Helsinki Stock Exchange is cheap

Valuation methods: Valuation multiples

Kontakter

Om Demant A/S

Vedhæftninger

Tilmeld dig vores nyhedsbrev - ingen konto nødvendig!